Assessment of anti-metastatic effects of anticoagulant and antiplatelet agents using animal models of experimental lung metastasis

Methods in Molecular Biology

Volumn 663, Issue , 2010, Pages 241-259

  Amirkhosravi, Ali ^a   Mousa, Shaker A ^b   Amaya, Mildred ^a   Meyer, Todd ^a   Davila, Monica ^a   Robson, Theresa ^a   Francis, John L ^a  

^a FLORIDA HOSPITAL   (United States)

^b Pharmaceutical Research Institute at Albany   (United States)

Author keywords

anti platelet drugs; Anticoagulants; experimental models; metastasis; tissue factor

Indexed keywords

ANIMALIA; RODENTIA;

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; ENOXAPARIN; THROMBOPLASTIN; WARFARIN;

ANIMAL; ARTICLE; BLOOD CLOTTING; DRUG ANTAGONISM; DRUG EFFECT; EXPERIMENTAL NEOPLASM; HUMAN; LUNG TUMOR; METASTASIS; MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; BLOOD COAGULATION; CELL LINE, TUMOR; ENOXAPARIN; HUMANS; LUNG NEOPLASMS; MICE; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; PLATELET AGGREGATION INHIBITORS; THROMBOPLASTIN; WARFARIN;

EID: 77957661965     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-60761-803-4_10     Document Type: Article

References (59)

1. De Cicco, M. (2004) The prothrombotic state in cancer: Pathogenic mechanisms Crit Rev Oncol Hematol 50, 187-96.
2. Hillen, H.F. (2000) Thrombosis in cancer patients Ann Oncol (Suppl. 3) 11, 273-76.
3. Buller, H.R., van Doormaal, F.F., van Sluis, G.L., and Kamphuisen, P.W. (2007) Cancer and thrombosis: From molecular mechanisms to clinical presentations J Thromb Haemost 5(Suppl.1), 246-54.
4. Trousseau, A. Phlegmasia alba dolens. In: Baillier, J., ed. Clinique de l'Hotel-Dieu de Paris, 2nd edition. London: New Sydenham Society;1865:654-6.
5. Varki, A. (2007) Trousseau's syndrome: Multiple definitions and multiple mechanisms Blood 110, 723-9.
6. Langer, F., Spath, B., Haubold, K., et al. (2008) Tissue factor procoagulant activity of plasma microparticles in patients with cancerassociated disseminated intravascular coagulation Ann Haematol 87, 451-7.
7. Sun, N., McAfee, W., Hum, G., and Weiner J.M. (1979) Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part 1. Coagulation studies Am J Clin Pathol 71, 10-6.
8. Kies, M.S., Posch, J.J., Giolama, J.P., and Rubin, R.N. (1980) Hemostatic function in cancer patients Cancer 46, 831-7.
9. Edwards, R.L., Rickles, F.R., Moritz, T.E. et al. (1987) Abnormalities of blood coagulation tests in patients with cancer Am J Clin Pathol 88, 596-602.
10. Davis, R.B., Theologides, A., and Kennedy, B.J. (1969) Comparative studies of blood coagulation and platelet aggregation in patients with cancer and non-malignant diseases Ann Int Med 71, 67-80.
11. Francis, J.L., and Amirkhosravi, A. (2002) Effect of antihemostatic agents on experimental tumor dissemination Semin Thromb Hemost 28, 29-38.
12. Rickles, F.R., Edwards, R.L., Barb, C., and Cronlund, M. (1983) Abnormalities of blood coagulation in patients with cancer: Fibrinopeptide A generation and tumor growth Cancer 51, 301-7.
13. Francis, J.L., Francis, D.A., and Gunathilagan, G.J. (1994) Assessment of hypercoagulability in patients with cancer using the sonoclot analyzer and thromboelastography Thromb Res 74, 335-46.
14. Wojtukiewicz, M.Z., Sierko, E., Klement, P., and Rak, J. (2001) The hemostatic system and angiogenesis in malignancy Neoplasia 3, 371-84.
15. Bogdanov, V.Y., Balasubramanian, V., Hathcock, J., et al. (2003) Alternatively spliced human tissue factor: A circulating, soluble, thrombogenic protein Nat Med 9, 458-62.
16. Giesen, P.L., Rauch, U., Bohrmann, B., et al. (1999) Blood borne tissue factor: Another view of thrombosis Proc Natl Acad Sci USA 96, 2311-5.
17. Hron, G., Kollars, M., Weber, H., et al. (2007) Tissue factor positive microparticles: Cellular origin and association with coagulation activation in patients with colorectal cancer Thromb Haemost 97, 119-23.
18. Langer, F., Chun, F.K., Amirkhosravi, A., et al. (2007) Plasma tissue factor antigen in localized prostate cancer: Distribution, clinical significance and correlation with haemostatic activation markers Thromb Haemost 97, 464-70.
19. Del conde, I., Bharwani, L.D., Dietzen, D.J., et al. (2006) Microvesicle-associated tissue factor and Trousseau's syndrome J Thromb Haemost 5, 70-74.
20. Davila, M., Amirkhosravi, A., Coll, E., Desai, H., Robles, L., Colon, J., Baker, C.H., and Francis, J.L. (2008) Tissue factor-bearing microparticles derived from tumor cells: Impact on coagulation activation Thromb Haemost 6, 1517-24.
21. Bromberg, M.E., Konigsberg, W., Madison, J., et al. (1995) Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation Proc Natl Acad Sci USA 92, 8205-9.
22. Mueller, B.M., and Ruf, W. (1998) Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis J Clin Invest 101, 1372-8.
23. Tsopanoglou, N.E., and Maragoudakis, M.E. (1999) On the mechanism of thrombininduced angiogenesis. Potentiation of vascular endothelial growth factor activity on endothelial cells by upregulation of its receptors J Biol Chem 274, 23969-76.
24. Tsopanoglou, N.E., and Maragoudakis. M.E. (2004) Role of thrombin in angiogenesis and tumor progression Semin ThrombHemost 30, 63-9.
25. Lewis, G.P. (1965) Method using orthotolidine for the quantitative determination of hemoglobin in serum and urine J Clin Pathol 18, 235-9.
26. Amirkhosravi, M., and Francis, J.L. (1993) Procoagulant effects of the MC28 fibrosarcoma cell line in vitro and in vivo Br J Haematol 85, 736-44.
27. Edwards, R.L., Silver, J., and Rickles, F.R. (1993) Human tumor procoagulants: Registry of the Subcommittee of Haemostasis of the Scientific and Standardization Committee, International Society on Thrombosis and Haemostasis Thromb Haemost 69, 205-13.
28. Adamson, A.S., Luckert, P., Pollard, M., et al. (1994) Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer Br J Cancer 69, 286-90.
29. Amirkhosravi, M., and Francis, J.L. (1995) Coagulation activation by MC28 fibrosarcoma cells facilitates lung tumor formation Thromb Haemost 73, 59-65.
30. McCulloch, P., and George, W.D. (1987) Warfarin inhibition of metastasis: The role of anticoagulation Br J Surg 74, 879-83.
31. Palumbo, J.S., and Degen, J.L. (2001) Fibrinogen and tumor cell metastasis Hemostasis 31(Suppl 1), 11-15.
32. Mousa, S.A., Linhardt, R., Francis, J.L., and Amirkhosravi, A. (2006) Anti-metastatic effect of a non-anticoagulant low-molecular weight heparin versus the standard lowmolecular- weight heparin, enoxaparin Thromb Haemost 96, 816-21.
33. Mousa, S.A., and Mohamed, S. (2004) Antiangiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: Anti-cancer efficacy Oncol Rep 12, 683-8.
34. Mousa, S.A., and Mohamed, S. (2004) Inhibition of endothelial cell tube formation by the low molecular weight heparin tinzaparin, is mediated by tissue factor pathway inhibitor Thromb Haemost 92, 627-33.
35. Lupu, C., Poulson, E., Toque feuil, S., et al. (1999) Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture Arterioscler Thromb Vasc Biol 19, 2251-62.
36. Kim, Y.J., Borsig, L., Varki, N.M., et al. (1998) P-selectin deficiency attenuates tumor growth and metastasis Proc Natl Acad Sci USA 95, 9325-30.
37. Ludwig, R.J., Boehme, B., Podda, M., et al. (2004) Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis Cancer Res 64, 2743-50.
38. Nakamori, S., Kameyama, M., Imaoka, S., et al. (1993) Increased expression of Sialyl Lewis X antigen correlates with poor survival in patients with colorectal carcinoma: Clinicopathological and immunohistochemical study Cancer Res 53, 32-36.
39. Nakayama, T., Watanabe, M., Katsumata, T., et al. (1995) Expression of sialyl Lewis(a) as a new prognostic factor for patients with advanced colorectal carcinoma Cancer 75, 2051-6.
40. Jorgensen, T., Berner, A., Kaalhus, O., et al. (1995) Upregulation of the oligosaccharide sialyl Lewis X: A new prognostic parameter in metastatic prostate cancer Cancer Res 55, 1817-9.
41. Morrow, D.A., Murphy, S.A., McCabe, C.H., et al. (2005) Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): Results of the PROXIMATE-TIMI 27 trial Eur Heart 26, 682-8.
42. Snyder, L.A., Rudnick, K.A., Tawadros, R., et al. (2007) Expression of human tissue factor under the control of the mouse tissue factor promoter mediates normal hemostasis in knock-in mice J Thromb Haemost 6, 306-14.
43. Gemmell, C.H., Broze, G.J., Turitto, V.T., and Nemerson, Y. (1990) Utilization of a continuous flow reactor to study the lipoprotein-associated coagulation inhibitor (LACI) that inhibits tissue factor Blood 76, 2266-71.
44. Bajaj, M.S., Birktoft, J.J., Steer, S.A., and Bajaj, S.P. (2001) Structure and biology of tissue factor pathway inhibitor Thromb Haemost, 86, 959-72.
45. Rapp, J.H., Pan, X.M., Ghermay, A., et al. (1997) A blinded trial of local recombinant tissue factor pathway inhibitor versus either local or systemic heparin in a vein bypass model J Vasc Surg 25, 726-9.
46. Amirkhosravi, A., Meyer, T., Chang, J.Y., et al. (2002) Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma Thromb Haemost 87, 930-6.
47. Fidler, I.J. (1970) Metastasis: Quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5 deoxyuridine J Natl Cancer Inst 45, 773-82.
48. Hembrough, T.A., Swartz, G.M., Papathanassiu, A., et al. (2003) Tissue factor/ factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism Cancer Res 63, 2997-3000.
49. Warren, B.A. The micro-injury hypothesis and metastasis. In: Honn, K.V., and Sloane, B.F., eds. Hemostatic Mechanisms and Metastasis.Boston: M. Nijhoff;1984:56.
50. Nieswandt. B., Hafner, M., Echtenacher, B., et al. (1999) Lysis of tumor cells by natural killer cells in mice is impeded by platelets Cancer Res 59, 1295.
51. Lerner, W.A., Pearlstein, E., Ambrogio, C., et al. (1983) A new mechanism for tumorinduced platelet aggregation: Comparisons with mechanisms shared by other tumors with possible pharmacologic strategy towards prevention of metastases Int J Cancer 31, 463-9.
52. Gasic, G.J., Gasic, T.B., and Stewart, C.C. (1968) Antimetastatic effects associated with platelet reduction Proc Natl Acad Sci USA 61, 46-52.
53. Gasic, G.J., Gasic, T.B., and Murphy, S. (1972) Anti-metastatic effect of aspirin Lancet 2, 934.
54. Tzanakakis, G.N., Agarwal, K.C., and Vezeridis, M.P. (1993) Prevention of human pancreatic cancer cell-induced hepatic metastasis in nude mice by dipyridamole and its analog RA-233 Cancer 71, 2466-71.
55. Karpatkin, S., Pearlstein, E., Ambrogio, C., et al. (1988) Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo J Clin Invest 81, 1012-9.
56. Amirkhosravi, A., Amaya, M., Siddiqui, F., et al. (1999) Blockade of GpIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis Platelets 10, 285-92.
57. Amirkhosravi, A., Mousa, S.A., Amaya, M., et al. (2003) Inhibition of tumor cell-induced platelet aggregation and lung metastasis by oral GpIIb/IIIa antagonist XV454 Thromb Haemost 90, 549-54.
58. Mousa, S.A., Forsythe, M., Bozarth, J., et al. (1998) XV454, a novel non-peptide small molecule platelet GpIIb/IIIa antagonist with comparable platelet aIIbβ3-binding kinetics to c7E3 J Cardiovasc Pharmacol 32, 736-44.
59. Kuderer, N.M., Khorana, A.A., Lyman, G.H., and Francis, C.W. (2007) A metaanalysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment Cancer 110, 1149-61.